Open tender · Germany · Contract notice
Open House Originale Rabattverträge 2025-02- Elvitegravir/Cobicistat/Emtricitabin/Tenofoviralafenamidfumarat (Genvoya(R))
Techniker Krankenkasse in Germany is inviting bids for “Open House Originale Rabattverträge 2025-02- Elvitegravir/Cobicistat/Emtricitabin/Tenofoviralafenamidfumarat (Genvoya(R))”. Bids close on 28 February 2027.
The work
Closing discount contracts for the drug Genvoya(R) with pharmaceutical entrepreneurs via an Open-House procedure.
- Must be a pharmaceutical entrepreneur with a valid marketing authorization for Genvoya(R).
- Must have a legal seat in the EU/EEA or Germany.
Key facts
- Contract period
- Max 24 months from 01.03.2025
What it takes to qualify
Worth a closer look
- The tender document is a description of a process and does not contain a standard bid submission form with specific financial or technical requirements like EMD, tender fee, or detailed submission mechanics.
- The 'Teilnahme- und Eignungsvoraussetzungen im Open-House-Verfahren' section is a heading but the details are in the 'Selection criteria (detail)' section.
Policy conditions
No reservation, preference or local-content restriction.
Documents to submit
- Eigenerklärung zur Zulassung und zum Unternehmen (Anlage 4 zum Vertrag)Self-declaration of being a pharmaceutical entrepreneur and having a valid marketing authorization.